Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fon-2021-1277

S Ibrahim, S Kurley, K Covington, S Arron and A Wysong contributed to the conception and design of the study. S Ibrahim, J Kasprzak, S Kurley, K Covington, A Farberg, S Trotter, K Reed, D Brodland, S Koyfman, A Somani, S Arron and A Wysong contributed to acquisition of data. M Hall, A Fitzgerald, J Siegel, S Kurley, K Covington and M Goldberg contributed to the analysis and interpretation of data. J Siegel and K Covington performed statistical analysis of data. S Ibrahim, M Hall, A Fitzgerald, S Kurley and A Wysong drafted the manuscript. All authors have contributed important intellectual content for critically revising the manuscript, take responsibility for integrity of the data and approve the manuscript in its final form.

The authors would like to thank the following individuals and centers for their contributions to this project: J Toyohara (Adult and Pediatric Dermatology, PC), M Gharia (Ascension/Columbia St. Mary's), C Schmults (Brigham and Women's Hospital), Y Xia (Brooke Army Medical Center), N Ezra (California Dermatology Institute), N Gharavi (Cedars Sinai), N Cleaver (Cleaver Dermatology), F Samie (Columbia University), T Schlesinger (Dermatology & Laser Center of Charleston), G Mendese (Dermatology & Skin Health), T Blalock (Emory University), J Boyer (John Boyer, MD), S Kwatra (Johns Hopkins), J Lyons (Mary Bird Perkins Cancer Center), L Toylaymat and S Fosko (Mayo Clinic, Florida), T Hansen (McFarland Clinic), D Papadopoulos (MetroDerm PC), T Knackstedt (MetroHealth, Cleveland), D Rivlin (Miami Beach Skin Center – Skin & Cancer Assoc.), N Braghiroli (Miami Cancer Institute – Baptist Health), M Fazio (Michael J. Fazio, MD, Inc.), J Fazio (Medical College of Wisconsin), J Zager (Moffitt Cancer Center), H Korasani (Mt Sinai), E Bailey (Naaman Clinic), B Brockstein (Northshore University HealthSystem), S Yoo and P Gerami (Northwestern University), C Chung (Ohio State University), A Bar (Oregon Health & Science University), R Neves (Penn State Hershey), J Campana (Porter Adventist/Centura Health Research Center), D Spearman (Premier Health – Parkview), N Fernandes (Prestige Dermatology & Medical Advisors), C Love (Radiant Complexions – Iowa Dermatology), K Brady (Roswell Park), J Canueto (Salamanca University Hospital – Spain), H Greenway (Scripps Health), R Griego (Skin Cancer Specialists), J DeBloom (South Carolina Skin Cancer Center), M Guenther (St. Elizabeth Physicians), R Behshad (St. Louis University), M Murphy (The Indiana Skin Cancer Center), J Curry (Thomas Jefferson University Hospital), P Scumpia (UCLA Heallth), C Huang (University of Alabama), T Jennings (University of Arkansas), J Mammen (University of Kansas MC), I Maher (Saint Louis University/University of Minnesota), E Smith (University of Missouri), J Newman (University of Pennsylvania), L Ferris (University of Pittsburgh Medical Center), G Kim (University of Southern California), M Fleming (University of Tennessee Health Science Center), J Lewis and A Ward (University of Tennessee Medical Center, Knoxville), K Duffy (University of Utah), C Weinberger (University of Vermont), D Beynet (VA – Los Angeles), D Pariser (Virginia Clinical Research, Inc.), C Regula (Vujevich Dermatology Associates), J Ouellette (Wright State – Miami Valley Hospital South, OH), and F Monzon, R Cook, J Wilkinson, V Salas, L Meldi Sholl, C Bailey, K Oelschlager, C Johnson and K Carter (Castle Biosciences, Inc.).

Materials and funding for this study were provided by Castle Biosciences, Inc. S Ibrahim receives research funding from Regeneron and funding for lectures/speakers bureau services from Regeneron and Genentech; M Hall, A Fitzgerald, J Siegel, S Kurley, K Covington and M Goldberg are employees and options holders for Castle Biosciences, Inc.; A Farberg serves as a consultant for Castle Biosciences, Inc. and is on the advisory boards for Eli Lilly, SunPharma, Orthodermatologics, Boehringer Ingelheim, Incyte, Amgen, Galderma, Novartis, and Pfizer; S Koyfman receives research funding and consulting fees from Merck, research funding from Bristol Myers Squibb, and honoraria from UpToDate; S Arron has been an employee of Rakuten Medical and is currently a consultant for Castle Biosciences, Inc. and Enspectra Health; and A Wysong serves on the WDS and ACMS Boards of Directors and is a Trustee for the Dermatology Foundation (nonmonetary service) and Castle Biosciences, Inc. Steering Committee (nonmonetary service). All remaining authors participated as investigators for Castle Biosciences, Inc. during this study. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

The authors have obtained appropriate institutional review board (IRB) approval via Western IRB and informed consent has been obtained from human study participants as required.

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/